Rosen Law Investigates Simulations Plus Over Alleged Misleading Sales Disclosures
- Rosen Law opened an investigation into Simulations Plus for allegedly issuing materially misleading business information after a Benzinga report.
- Simulations Plus reported Q3 sales of $20.4M, 10% growth, yet missed consensus estimates and raised disclosure concerns.
- Probe questions Simulations Plus' revenue guidance accuracy, signaling litigation risk and governance, compliance, investor-relations consequences.
Legal Inquiry Opens Into Simulations Plus' Sales Disclosures
Rosen Law Firm is opening an investigation into Simulations Plus Inc. over allegations that the company issues materially misleading business information, the firm says. The probe, launched on behalf of shareholders, follows a July 15, 2025 Benzinga report that cites weakening demand and a softened outlook communicated around the release of Simulations Plus' third-quarter 2025 results.
Simulations Plus reports third-quarter sales of $20.4 million, a 10% year-on-year increase that nonetheless misses consensus estimates cited by market sources. Benzinga also references preliminary June sales guidance of $19.0 million to $20.0 million that contrasts with a higher consensus figure, creating the basis for Rosen Law’s inquiry into whether public disclosures accurately reflect the company’s demand trends and outlook. The firm frames the matter as potential securities claims related to corporate disclosures rather than product performance.
The investigation underscores scrutiny on how clinical and drug-development software vendors communicate near-term demand and revenue visibility to investors and counterparties. Simulations Plus, known for pharmacokinetic and pharmacodynamic simulation tools used in drug development, operates in a niche where forecasting project intake and licensing activity affects perceived growth trajectories. Rosen Law’s action signals potential litigation risk stemming from gaps between preliminary guidance, public statements and final reported results, with possible consequences for governance, compliance and investor relations if claims proceed.
How Shareholders Can Engage
Rosen Law says eligible shareholders who purchased Simulations Plus securities may join a contingency-fee class action and can submit claims through the firm’s online intake forms, by toll-free phone or email. The firm emphasizes no out-of-pocket fees for participants and urges investors seeking representation to consider experienced counsel.
Rosen Law’s Background
Rosen Law highlights its securities-class-action track record, noting past large recoveries and industry rankings, including a top ranking from ISS Securities Class Action Services and recognition for founding partner Laurence Rosen by Law360. The firm presents these credentials as part of its outreach to potentially affected Simulations Plus shareholders.